Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax

Blood Adv. 2022 May 24;6(10):3068-3071. doi: 10.1182/bloodadvances.2021006949.

Authors

Anna Candoni¹, Chiara Callegari¹, Maria Elena Zannier¹, Renato Fanin^{1

2}

Affiliations

¹ Division of Hematology and Stem Cell Transplantation, ASUFC, Udine, Italy; and.
² DAME, University of Udine, Udine, Italy.

No abstract available

MeSH terms

Antibody Formation
Bridged Bicyclo Compounds, Heterocyclic
COVID-19* / prevention & control
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
RNA, Messenger
Sulfonamides
Vaccination

Substances

Bridged Bicyclo Compounds, Heterocyclic
RNA, Messenger
Sulfonamides
venetoclax